| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT02235545 |
| P17 | country | Canada | Q16 |
| Japan | Q17 | ||
| United States of America | Q30 | ||
| Belgium | Q31 | ||
| Portugal | Q45 | ||
| Poland | Q36 | ||
| Germany | Q183 | ||
| P582 | end time | 2021-07-01 | |
| P1050 | medical condition | heart failure | Q181754 |
| tachycardia | Q209583 | ||
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 1725 | |
| P6153 | research site | Texas A&M University | Q49212 |
| Lehigh Valley Hospital | Q6518847 | ||
| Maimonides Medical Center (Jewish) | Q6735870 | ||
| INTEGRIS Baptist Medical Center | Q14708458 | ||
| ZOL Hospital | Q15884211 | ||
| Royal Alexandra Hospital | Q29492129 | ||
| Tokyo Women's Medical University University Aoyama Hospital | Q30260299 | ||
| Minneapolis Heart Institute Foundation | Q30272717 | ||
| Genesys Regional Medical Center | Q30280511 | ||
| Kingston General Hospital | Q3145338 | ||
| Lancaster General Hospital | Q6483178 | ||
| P580 | start time | 2014-08-01 | |
| P8363 | study type | observational study | Q818574 |
| P1476 | title | Optisure Lead Post Approval Study |
Search more.